Landscapes / Targets
TIGIT
12 drugs act on TIGIT, in 65 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs12
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
TIGIT antibody |
GSK +1 |
Phase 3 | 31 Dec 2026Phase 1 trial completes | ||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Neoplasms, Lung Cancer, Non-Small Cell and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Roche · Public ROG.SW |
Phase 3 | 31 Dec 2026Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Liver Cancers, Metastatic Colorectal Cancer and 5 more | ||||
| Open drug page | |||||
TIGIT antibody |
Arcus Biosciences +1 · Public GILD |
Phase 3 | Mar 2027Phase 2 trial completes | ||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Metastatic Urothelial Cancer and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Lymphoma and 7 more | ||||
| Open drug page | |||||
PD-1/TIGIT bispecific antibody |
AstraZeneca · Public AZN |
Phase 3 | 4 May 2027Phase 2 trial completes | ||
| Next date | 4 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Gastric Cancer and 34 more | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 2 | 10 Feb 2027Phase 2 trial completes | ||
| Next date | 10 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Hepatocellular | ||||
| Open drug page | |||||
— |
Akeso · Public 9926.HK |
Phase 2 | May 2027Phase 1/2 trial completes | ||
| Next date | May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Biliary Tract Cancer and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Merck & Co. · Public MRK |
Phase 1/2 | 13 Feb 2032Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 13 Feb 2032 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung | ||||
| Open drug page | |||||
— |
Huahai Pharmaceutical (Huaota) · Public 600521.SS |
Phase 1/2 | — | ||
| Also tested for | Advanced Solid Tumor, NSCLC | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Locally Advanced or Metastatic Urothelial Carcinoma | ||||
| Open drug page | |||||
— |
BioNTech · Public BNTX |
Phase 1/2 | — | ||
| Also tested for | HCC, Liver Cancer | ||||
| Open drug page | |||||
— |
Phase 1 | 12 Nov 2027Phase 1 trial completes | |||
| Next date | 12 Nov 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 12 of 12 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026